Shares of Novartis India Ltd. experienced a significant uplift, climbing 4% in Monday's trading following the announcement of a major acquisition. The pharmaceutical firm confirmed it would acquire the 'Minipress' and 'Minipres' trademarks in India, along with certain related intellectual property rights, from Pfizer Inc. and Pfizer Products Inc. USA.
The total consideration for this strategic acquisition stands at ₹1,250 crore. Novartis India's board officially approved the transaction at a meeting held on September 7, subsequently executing an asset purchase agreement and trademark assignment deeds with the Pfizer entities.
Stock Performance and Market Reaction
Following the news, Novartis India's stock jumped by 3.65% to reach a high of ₹1,696.90 apiece on the BSE, up from its previous close of ₹1,637.10. The stock had opened at ₹1,651.50. Conversely, India-listed Pfizer Ltd. saw a slight decline, falling 0.52% to ₹4,589.65.
Details of the Acquired Trademarks
The acquired trademarks pertain to medications containing prazosin, primarily indicated in India for the treatment of high blood pressure and the management of urinary symptoms associated with benign prostatic hyperplasia. According to the company's exchange filing, Minipress XL recorded revenue of ₹228.60 crore based on IQVIA MAT July 2026 data. This product has demonstrated a compounded annual growth rate (CAGR) of 6.3% over the past four years, in a category that has grown by 9% overall during the same period.
Novartis India clarified that the transaction is not a related-party transaction, confirming that the counterparties, Pfizer Inc. and Pfizer Products Inc. USA, are not related to its promoter or promoter group.